{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:57:26Z","timestamp":1761058646920,"version":"3.37.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":9527,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[1989,8]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>Amineptine-induced immunoallergic hepatitis is unpredictable. It may be related to its oxidation into a reactive metabolite acting as hapten. We have looked for a possible genetic predisposition involving drug oxidation capacity and\/or cell defense mechanisms in nine patients with previous amineptine hepatitis. Drug oxidation capacity was assessed using dextromethorphan, a test compound recently proposed as a substitute for debrisoquine. The eight patients tested had the extensive metabolizer phenotype. The susceptibility to amineptine metabolites was studied by an in <jats:italic toggle=\"yes\">vitro<\/jats:italic> test assessing the destruction of the patients\u2019 lymphocytes by reactive metabolites generated from amineptine by a standardized oxidation microsomal system. Lymphocyte death increased with the dose of amineptine (1 to 2.5 m<jats:italic toggle=\"yes\">M<\/jats:italic>); it was increased by preincubation with trichloropropene oxide, but was absent when amineptine was omitted or when the oxidation system was not operating. Mean lymphocyte death was twice higher in the nine patients with amineptine hepatitis than in 17 healthy controls. In contrast, when the test was performed with acetaminophen (3 to 10 m<jats:italic toggle=\"yes\">M<\/jats:italic>), lymphocyte death was similar in controls and in patients. Basal epoxide hydrolase activity toward benzo[a]pyrene-4,5-oxide and glutathi-one concentration was similar in lymphocytes from controls and patients. Family studies showed an increased susceptibility to amineptine metabolites in lymphocytes from several first-degree relatives of two patients. These results show that amineptine hepatitis occurs in patients with extensive dextromethorphan oxidation capacity but with an increased susceptibility to amineptine reactive metabolites, probably related to a genetic deficiency in a cell defense mechanism.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.1840100208","type":"journal-article","created":{"date-parts":[[2007,3,3]],"date-time":"2007-03-03T22:32:22Z","timestamp":1172961142000},"page":"168-173","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":40,"title":["Genetic predisposition to drug hepatotoxicity: Role in hepatitis caused by amineptine, a tricyclic antidepressant"],"prefix":"10.1097","volume":"10","author":[{"given":"Dominique","family":"Larrey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Berson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Habersetzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Tinel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Castot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9rard","family":"Babany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Lett\u00e9ron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Freneaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Loeper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Dansette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Pessayre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"10.1002\/hep.1840100208-BIB1","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.2042-7158.1977.tb11395.x","volume":"29","author":"Samanin","year":"1977","journal-title":"J Pharm Pharmacol"},{"key":"10.1002\/hep.1840100208-BIB2","volume-title":"A comprehensive survey of the literature on adverse drug reactions up to January 1985","author":"Stricker","year":"1985","unstructured":". Drug-induced hepatic injury. A comprehensive survey of the literature on adverse drug reactions up to January 1985. Amsterdam: Elsevier, 1985."},{"key":"10.1002\/hep.1840100208-BIB3","first-page":"3689","volume":"9","author":"Bories","year":"1980","journal-title":"Nouv Presse Med"},{"key":"10.1002\/hep.1840100208-BIB4","first-page":"915","volume":"6","author":"Andrieu","year":"1982","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1002\/hep.1840100208-BIB5","first-page":"242","volume":"11","author":"Gen\u00e8ve","year":"1987","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1002\/hep.1840100208-BIB6","first-page":"509","volume":"39","author":"Lefebure","year":"1984","journal-title":"Therapie"},{"key":"10.1002\/hep.1840100208-BIB7","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0006-2952(87)90289-9","volume":"36","author":"Gen\u00e8ve","year":"1987","journal-title":"Biochem Pharmacol"},{"key":"10.1002\/hep.1840100208-BIB8","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0006-2952(87)90290-5","volume":"36","author":"Gen\u00e8ve","year":"1987","journal-title":"Biochem Pharmacol"},{"key":"10.1002\/hep.1840100208-BIB9","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1016\/0006-2952(87)90614-9","volume":"36","author":"Gen\u00e8ve","year":"1987","journal-title":"Biochem Pharmacol"},{"key":"10.1002\/hep.1840100208-BIB10","first-page":"2308","volume":"43","author":"Spielberg","year":"1984","journal-title":"Fed Proc"},{"key":"10.1002\/hep.1840100208-BIB11","first-page":"143","volume-title":"Liver cells and drugs","volume":"164","author":"Larrey","year":"1988","unstructured":". Genetic factors in hepatotoxicity. In: ed. Liver cells and drugs, Vol. 164. London: John Libbey Eurotext, 1988: 143\u2013152."},{"key":"10.1002\/hep.1840100208-BIB12","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.1840060534","volume":"6","author":"Jacqz","year":"1986","journal-title":"Hepatology"},{"key":"10.1002\/hep.1840100208-BIB13","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/gut.25.10.1057","volume":"25","author":"Morgan","year":"1984","journal-title":"Gut"},{"key":"10.1002\/hep.1840100208-BIB14","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/0003-4819-105-2-179","volume":"105","author":"Shear","year":"1986","journal-title":"Ann Intern Med"},{"key":"10.1002\/hep.1840100208-BIB15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/clpt.1981.9","volume":"29","author":"Spielberg","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1002\/hep.1840100208-BIB16","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJM198109243051302","volume":"305","author":"Spielberg","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1002\/hep.1840100208-BIB17","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJM198511213132102","volume":"313","author":"Farrell","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1002\/hep.1840100208-BIB18","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1365-2125.1987.tb03230.x","volume":"24","author":"Larrey","year":"1987","journal-title":"Br J Clin Parmacol"},{"key":"10.1002\/hep.1840100208-BIB19","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/clpt.1985.235","volume":"38","author":"Schmid","year":"1985","journal-title":"Clin Pharmacol Ther"},{"key":"10.1002\/hep.1840100208-BIB20","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(84)92591-1","volume":"2","author":"K\u00fcpfer","year":"1984","journal-title":"Lancet"},{"key":"10.1002\/hep.1840100208-BIB21","first-page":"395","volume":"213","author":"Spielberg","year":"1980","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1002\/hep.1840100208-BIB22","first-page":"189","volume-title":"Variations in epoxide hydrolase activities in human liver and blood. In: Omenn GS, Gelboin HV, eds. Genetic variability in responses to chemical exposure, Banbury Report 16","author":"Glatt","year":"1984","unstructured":". Variations in epoxide hydrolase activities in human liver and blood. In: Omenn GS, Gelboin HV, eds. Genetic variability in responses to chemical exposure, Banbury Report 16. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory, 1984: 189\u2013203."},{"key":"10.1002\/hep.1840100208-BIB23","first-page":"342","volume":"13","author":"Jerina","year":"1977","journal-title":"Mol Pharmacol"},{"key":"10.1002\/hep.1840100208-BIB24","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/0003-2697(69)90064-5","volume":"27","author":"Tietze","year":"1969","journal-title":"Anal Biochem"},{"key":"10.1002\/hep.1840100208-BIB25","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","volume":"193","author":"Lowry","year":"1951","journal-title":"J Biol Chem"},{"key":"10.1002\/hep.1840100208-BIB26","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/0016-5085(88)90631-2","volume":"94","author":"Larrey","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1002\/hep.1840100208-BIB27","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/0041-008X(79)90452-6","volume":"49","author":"Pessayre","year":"1979","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1002\/hep.1840100208-BIB28","first-page":"1417","volume":"60","author":"Spielberg","year":"1977","journal-title":"J Clin Invest"},{"key":"10.1002\/hep.1840100208-BIB29","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(80)91554-8","volume":"1","author":"Batchelor","year":"1980","journal-title":"Lancet"},{"key":"10.1002\/hep.1840100208-BIB30","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1056\/NEJM198008073030602","volume":"303","author":"Wooley","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1002\/hep.1840100208-BIB31","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1399-6576.1985.tb02242.x","volume":"29","author":"Otsuka","year":"1985","journal-title":"Acta Anaesthesiol Scand"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.1840100208","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-198908000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T15:19:11Z","timestamp":1738941551000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-198908000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1989,8]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1989]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.1840100208","relation":{},"ISSN":["0270-9139"],"issn-type":[{"type":"print","value":"0270-9139"}],"subject":[],"published":{"date-parts":[[1989,8]]}}}